Safety of recombinant activated factor VII in randomized clinical trials.

BACKGROUND The use of recombinant activated factor VII (rFVIIa) on an off-label basis to treat life-threatening bleeding has been associated with a perceived increased risk of thromboembolic complications. However, data from placebo-controlled trials are needed to properly assess the thromboembolic risk. To address this issue, we evaluated the rate of thromboembolic events in all published randomized, placebo-controlled trials of rFVIIa used on an off-label basis. METHODS We analyzed data from 35 randomized clinical trials (26 studies involving patients and 9 studies involving healthy volunteers) to determine the frequency of thromboembolic events. The data were pooled with the use of random-effects models to calculate the odds ratios and 95% confidence intervals. RESULTS Among 4468 subjects (4119 patients and 349 healthy volunteers), 401 [corrected] had thromboembolic events (9.0%). [corrected] Rates of arterial thromboembolic events among all 4468 subjects were higher among those who received rFVIIa than among those who received placebo (5.5% vs. 3.2%, P=0.003). Rates of venous thromboembolic events were similar among subjects who received rFVIIa and those who received placebo (5.3% vs. 5.7%). Among subjects who received rFVIIa, 2.9% had coronary arterial thromboembolic events, as compared with 1.1% of those who received placebo (P=0.002). Rates of arterial thromboembolic events were higher among subjects who received rFVIIa than among subjects who received placebo, particularly among those who were 65 years of age or older (9.0% vs. 3.8%, P=0.003); the rates were especially high among subjects 75 years of age or older (10.8% vs. 4.1%, P=0.02). CONCLUSIONS In a large and comprehensive cohort of persons in placebo-controlled trials of rFVIIa, treatment with high doses of rFVIIa on an off-label basis significantly increased the risk of arterial but not venous thromboembolic events, especially among the elderly. (Funded by Novo Nordisk.).

[1]  F. Sellke,et al.  Safety and Efficacy of Recombinant Activated Factor VII: A Randomized Placebo-Controlled Trial in the Setting of Bleeding After Cardiac Surgery , 2009, Circulation.

[2]  U. Hedner,et al.  Factor VIIa and its potential therapeutic use in bleeding-associated pathologies , 2008, Thrombosis and Haemostasis.

[3]  J. Augoustides.  Letter by Augoustides regarding article, "Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery". , 2008, Circulation.

[4]  S. Mayer,et al.  Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. , 2008, The New England journal of medicine.

[5]  D. Thabut,et al.  Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial , 2008, Hepatology.

[6]  T. Abshire.  Safety update on recombinant factor VIIa in the treatment of congenital and acquired hemophilia. , 2008, Seminars in hematology.

[7]  A. Maas,et al.  RECOMBINANT FACTOR VIIA IN TRAUMATIC INTRACEREBRAL HEMORRHAGE: RESULTS OF A DOSE‐ESCALATION CLINICAL TRIAL , 2008, Neurosurgery.

[8]  Chris A Rogers,et al.  Increased Mortality, Postoperative Morbidity, and Cost After Red Blood Cell Transfusion in Patients Having Cardiac Surgery , 2007, Circulation.

[9]  Peter Kruse,et al.  Recombinant Activated Factor VII in Spinal Surgery: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial , 2007, Spine.

[10]  T. Brott,et al.  Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile , 2006, Transfusion.

[11]  U. Hedner.  Mechanism of action of factor VIIa in the treatment of coagulopathies. , 2006, Seminars in thrombosis and hemostasis.

[12]  J. Weinberger.  Recombinant activated factor VII for acute intracerebral hemorrhage. , 2006, Current cardiology reports.

[13]  Po-Huang Lee,et al.  Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. , 2006, American journal of surgery.

[14]  M. Braun,et al.  Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. , 2006, JAMA.

[15]  S. Mayer,et al.  Recombinant activated factor VII for acute intracerebral hemorrhage US phase IIA trial , 2006, Neurocritical care.

[16]  D. O'shaughnessy,et al.  Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. , 2005, British journal of anaesthesia.

[17]  A. Chuansumrit,et al.  Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study , 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[18]  J. Szer,et al.  Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation , 2005, Journal of thrombosis and haemostasis : JTH.

[19]  J. García-Valdecasas,et al.  Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[20]  J. Heit.  Venous thromboembolism: disease burden, outcomes and risk factors , 2005, Journal of thrombosis and haemostasis : JTH.

[21]  G. Klintmalm,et al.  Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[22]  R. Rossaint,et al.  Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. , 2005, The Journal of trauma.

[23]  E. Erhardtsen,et al.  A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects , 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[24]  R. Grounds,et al.  Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. , 2005, British journal of anaesthesia.

[25]  S. Seremetis,et al.  Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity—a rebuttal , 2005, Journal of thrombosis and haemostasis : JTH.

[26]  H. Büller,et al.  Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: A systematic review , 2005, Critical care medicine.

[27]  W. Bechstein,et al.  Recombinant Coagulation Factor VIIa in Major Liver Resection: A Randomized, Placebo-controlled, Double-blind Clinical Trial , 2005, Anesthesiology.

[28]  S. Mayer,et al.  Safety and Feasibility of Recombinant Factor VIIa for Acute Intracerebral Hemorrhage , 2005, Stroke.

[29]  D. Thabut,et al.  Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. , 2004, Gastroenterology.

[30]  P. Giangrande,et al.  Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven®) in children vs. adults with haemophilia A , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[31]  M. Wolzt,et al.  Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers , 2004, Thrombosis and Haemostasis.

[32]  R. Peters,et al.  Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers , 2003 .

[33]  R. Abbott,et al.  Age-related changes in risk factor effects on the incidence of thromboembolic and hemorrhagic stroke. , 2003, Journal of clinical epidemiology.

[34]  K. Kurth,et al.  Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial , 2003, The Lancet.

[35]  R. Peters,et al.  Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers , 2002, Circulation.

[36]  H. Büller,et al.  Ability of Recombinant Factor VIIa to Generate Thrombin During Inhibition of Tissue Factor in Human Subjects , 2001, Circulation.

[37]  M. Samama,et al.  An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. , 2000, Archives of internal medicine.

[38]  F R Rosendaal,et al.  Risk Factors for Venous Thrombotic Disease , 1999, Thrombosis and Haemostasis.

[39]  J. Boissel,et al.  The effect of recombinant factor VIIa (NovoSeven™) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0 , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.